New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 7, 2014
10:02 EDTCOTY, NMBL, EGHT, TEX, O, CQP, JAH, WWAV, RGP, TCO, PRGO, AGN, ACMP, BIN, TEVA, SGNT, MYL, ACT, ACRX, AKRX, ANIPOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: ANI Pharmaceuticals (ANIP) initiated with a Buy at Roth Capital... AcelRx (ACRX) initiated with an Outperform at RBC Capital... Actavis (ACT) initiated with an Outperform at RBC Capital... Akorn (AKRX) initiated with an Outperform at RBC Capital... Allergan (AGN) initiated with an Outperform at RBC Capital... Cheniere Energy Partners (CQP) initiated with an Outperform at Credit Suisse... Mylan (MYL) initiated with an Outperform at RBC Capital... Perrigo (PRGO) initiated with a Top Pick at RBC Capital... Realty Income (O) initiated with an Outperform at Oppenheimer... Sagent Pharmaceuticals (SGNT) initiated with an Underperform at RBC Capital... Taubman Centers (TCO) initiated with a Perform at Oppenheimer... Terex (TEX) initiated with a Hold at Jefferies... Teva (TEVA) initiated with a Sector Perform at RBC Capital... Regency Energy Partners (RGP) reinstated with an Outperform at Credit Suisse... 8x8, Inc. (EGHT) initiated with a Buy at Needham... Progressive Waste (BIN) initiated with an Underperform at Macquarie... WhiteWave Foods (WWAV) reinstated with an Overweight at JPMorgan... Nimble Storage (NMBL) initiated with a Buy at Stifel... Access Midstream (ACMP) coverage assumed with an Outperform at Credit Suisse... Jarden (JAH) initiated with an Outperform at RBC Capital... Coty (COTY) initiated with a Sector Perform at RBC Capital.
News For ANIP;ACRX;ACT;AKRX;AGN;CQP;MYL;PRGO;O;SGNT;TCO;TEX;TEVA;RGP;EGHT;BIN;WWAV;NMBL;ACMP;JAH;COTY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | all recent news | >>
April 21, 2015
08:54 EDTPRGO, TEVA, MYLPerrigo drops 2.2% to $193.74 after Teva proposes to acquire Mylan
Subscribe for More Information
08:52 EDTPRGO, TEVA, MYLTeva CEO says proposal compelling for both Teva, Mylan stockholders
Subscribe for More Information
08:50 EDTMYL, TEVATeva sees Mylan deal yielding non-GAAP EPS accretion in mid-teens in first year
Subscribe for More Information
08:48 EDTTEVA, MYLTeva expects proposed Mylan deal could be completed by year-end 2015
Subscribe for More Information
08:47 EDTMYL, TEVAMylan jumps 8% to $73.50 after Teva proposes $82 per share takeover bid
08:46 EDTTEVA, MYL, PRGOTeva offers to acquire Mylan for $82.00 per share in cash and stock
Teva Pharmaceutical Industries (TEVA) announced a proposal to acquire all of the outstanding shares of Mylan N.V. (MYL) in a transaction valued at $82.00 per Mylan share, with the consideration to be comprised of approximately 50% cash and 50% stock. The Teva cash and stock proposal provides Mylan stockholders with a substantial premium and immediate cash value, as well as significant potential for future value creation through participation in a financially and commercially stronger company. Tevaís proposal also provides Mylan stockholders with a more attractive alternative to Mylanís proposed acquisition of Perrigo Company plc (PRGO), as announced on April 8, 2015, as well as to Mylan on a standalone basis. Tevaís proposal would provide Mylan stockholders with consideration representing a 37.7% premium to the stock price of Mylan on April 7, 2015, which is the last day of trading prior to Mylanís press release regarding its unsolicited proposal for Perrigo, and a 48.3% premium to the unaffected stock price of Mylan on March 10, 2015, which is the last day of trading prior to widespread speculation of a transaction between Teva and Mylan. The proposed combination of Teva and Mylan would create a leading company in the pharmaceutical industry, well positioned to transform the global generics space. The combined company would leverage its significantly more efficient and advanced infrastructure, with enhanced scale, production network, end-to-end product portfolio, commercialization capabilities and geographic reach. With this platform, the combined company would focus on complex technologies and more durable and sustainable products, in combination with robust capabilities in specialty drug development and commercialization. As a result, the combined company would have a unique and differentiated business model addressing significant trends and discontinuities prevailing today among patients and healthcare systems around the world. The combined company would also have an enhanced financial profile, creating the opportunity for rapid deleveraging and the funding of future growth Ė in generics, specialty and the intersection of the two.
08:45 EDTTEVA, MYLTeva offers to acquire Mylan for $82.00 per share in cash and stock
Subscribe for More Information
08:41 EDTPRGO, MYL, TEVAOptions expected to be active
Options expected to be active: UA TEVA PRGO MYL UTX QCOM VMW HOG CMG IBM VZ
06:01 EDTMYL, TEVATeva bid for Mylan could come today, Bloomberg reports
Subscribe for More Information
April 20, 2015
19:54 EDTMYLMylan looks to invest $5B in Indian operations, Times of India says
Mylan is looking to invest $5B to expand operations in India's Andhra Pradesh region, reports the Times of India, citing statements by Mylan SVP, legal, Rajeev Mukundan in a meeting with the US-India Business Council delegation. Reference Link
18:29 EDTWWAVWhiteWave Foods initiated with a Neutral at Janney Capital
Target $46.
16:22 EDTACTActavis reports CCO Charles Mayr to retire for health reasons
Subscribe for More Information
11:40 EDTTEVATeva may pay $512M to settle claims of delaying generic Provigil, Reuters says
Subscribe for More Information
10:00 EDTBINOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:46 EDTCOTYCoty names Elio Leoni Sceti as CEO; Bart Brecht to remain chairman
Subscribe for More Information
08:12 EDTACTActavis's BOTOX label approved by FDA for spasticity treatment
Subscribe for More Information
07:35 EDTBINProgressive Waste downgraded on growth outlook at RBC Capital
As noted earlier, RBC Capital downgraded Progressive Waste to Sector Perform from Outperform. The firm lowered its organic growth outlook for the company based on its channel checks which suggest a soft Q1 performance. Target to $31 from $34.
07:18 EDTACTAmerican Academy of Neurology to hold annual meeting
Subscribe for More Information
06:39 EDTTEVA, MYL, PRGOCiti believes Teva, Mylan deal would have to be friendly
Subscribe for More Information
06:24 EDTBINProgressive Waste downgraded to Sector Perform from Outperform at RBC Capital
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use